ICON Partners with Korea National Enterprise for Clinical Trials

Dublin, Ireland, 3 October, 2012 – ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, and Korea National Enterprise for Clinical Trials (KoNECT) today announced they have signed a  partnership agreement that aims to advance the clinical trials industry in South Korea.

Through the agreement, ICON and KoNECT will collaborate on a series of educational events for local and multinational pharmaceutical companies, investigators and industry officials.  The programmes aim to further enhance the already high standards of clinical research in South Korea and will kick off with an oncology trials seminar in Seoul on October 26th.

"South Korea has become a key country for clinical development and ICON has had a well-established presence there since 2005," commented Wei Ming Goh, ICON's Vice President, Asia-Pacific. "Our agreement with KoNECT supports our mutual interest in developing and growing the clinical research industry in South Korea and demonstrates our on-going commitment to the Asia Pacific region."

KoNECT President, Professor Sang-Goo Shin, added, "We are delighted to collaborate with a leading clinical research organisation such as ICON that has a wealth of expertise in both local and global clinical development programmes. Together we can develop high quality clinical research professionals and a clinical trials infrastructure that can support the increased demand from local and global pharma companies."

ICON is one of the leading CROs in Asia-Pacific, employing over 1,400 staff in the region from locations in 13 countries. Learn more about ICON's capabilities in Asia-Pacific

About KoNECT
Established in 2007 with the support of the South Korean government, academic institutions and life-science industries, KoNECT provides clinical research resources, training and support. KoNECT's vision is to establish an advanced clinical trial infrastructure and develop the nation's biopharmaceutical industry to serve as an international hub for clinical trials. It has recently adopted a certificate system for clinical trial experts, and is focusing on the running of educational programs and making partnership with global organisations.

About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has 9,200 employees, operating from 82 locations in 40 countries.

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.